Pfizer's Dolsten On Finding Ways To “Accelerate External Science”
Part 2 Of 2
Worldwide President of R&D Mikael Dolsten talked to Scrip about Pfizer's busy business development track record and the company's ambition to maintain its leadership in breast cancer.
You may also be interested in...
Chief development officer William Pao will depart the company in a sudden transition after being recruited from Roche. Pfizer insiders Chris Boshoff and Mikael Dolsten will fill the roles.
Pfizer and Seagen reportedly are in merger discussions, signaling Pfizer’s willingness to invest significantly in antibody-drug conjugates (ADCs) for cancer.
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.